• Biodefense, FDA, national security, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; H.R. 2670 - National Defense Authorization Act for Fiscal Year 2024; issues relating to pandemic preparedness and infectious disease education; issues relating to step therapy; issues relating to health care extenders; issues related to federal contracting relating to biopharmaceutical manufacturers
• Medicare, Medicaid, and other drug pricing issues relating to biopharmaceutical manufacturers
• Patent issues relating to biopharmaceutical manufacturers; intellectual property rights; issues relating to WTO TRIPS waivers

Duration: August 1, 2016 to present

General Issues: Health Issues, Medicare/Medicaid, Copyright/Patent/Trademark, Taxation/Internal Revenue Code, Budget/Appropriations

Spending: about $9,040,000 (But it's complicated. Here's why.)

It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.

Agencies lobbied since 2016: U.S. Senate, House of Representatives, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), White House Office, Centers For Medicare and Medicaid Services (CMS), Office of the Vice President of the United States, Patent & Trademark Office (PTO)

Related Foreign Entities: Sanofi S.A. (Paris, FRA); contribution to lobbying: $0; ownership 22%